| Lennox-Gastaut Syndrome
Banzel vs Qudexy XR
Side-by-side clinical, coverage, and cost comparison for lennox-gastaut syndrome.Deep comparison between: Banzel vs Qudexy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQudexy has a higher rate of injection site reactions vs Banzel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qudexy but not Banzel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Banzel
Qudexy
At A Glance
Oral
Twice daily
Sodium channel modulator
Oral
Once daily
Broad-spectrum anticonvulsant
Indications
- Lennox-Gastaut Syndrome
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
Dosing
Lennox-Gastaut Syndrome (pediatric, 1 to <17 years) Starting dose approximately 10 mg/kg/day in two divided doses; increase by 10 mg/kg every other day to maximum 45 mg/kg/day (not to exceed 3200 mg/day); administer with food.
Lennox-Gastaut Syndrome (adults, >=17 years) Starting dose 400-800 mg/day in two divided doses; increase by 400-800 mg every other day to maximum 3200 mg/day; administer with food.
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Contraindications
- Familial Short QT syndrome
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
Adverse Reactions
Most common (>=10%) Headache, dizziness, fatigue, somnolence, nausea
Serious Suicidal behavior and ideation, CNS reactions, QT shortening, multi-organ hypersensitivity/DRESS, leukopenia
Postmarketing Stevens-Johnson syndrome and other serious skin rashes with mucosal involvement
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Pharmacology
Rufinamide is an antiepileptic triazole derivative whose principal mechanism of action is modulation of sodium channel activity, specifically prolonging the inactive state of the channel to limit sustained repetitive neuronal firing.
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Banzel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (0/12)
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Banzel
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Banzel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Epilepsy (Seizures): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Qudexy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BanzelView full Banzel profile
QudexyView full Qudexy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.